Donanemab (Kisunla) - A GP guide to the anti-amyloid therapies

After many years, something new for treating Alzheimer's disease has finally arrived.

Donanemab (Kisunla) is a monoclonal antibody recently approved for the treatment of early Alzheimer's disease, specifically for patients with mild cognitive impairment or mild dementia and confirmed amyloid pathology.

This Healthed Webcast will explain the evidence of its effectiveness in slowing cognitive and functional decline, with the greatest benefit being seen in early-stage patients. In addition, it will discuss the practical aspects of the treatment including patient selection, assessment, referral process as well as how the monthly IV infusions are delivered, monitored, and potential side effects. It will also address the reality that the effectiveness of donanemab is not universal and careful patient selection and managing expectations is important.

Scientia Prof Henry Brodaty AO will be joined by an expert faculty, covering a range of topics relevant to primary care:

• Early menopause - Dr Sonia Davison
• LDL and cardiovascular disease - Prof Andrew Sindone
• Autism spectrum disorder in children - A/Prof Daryl Efron